Table 3.
Oncofertility Options and Scores (%) for Breast Cancer in Limited versus Optimum Resource Settings, based on empirical data from 39 surveyed centers in Repro-Can-OPEN Study Part I & II [14, 15]
| Oncofertility Options and Scores (%) for Breast Cancer | Centers with Limited Resource Settings (Repro-Can-OPEN Study I) (n = 14) |
Centers with Optimum Resource Settings (Repro-Can-OPEN Study II) (n = 25) |
|---|---|---|
| Available fertility preservation options before anticancer treatment | ||
| Embryo freezing | 55.35 | 66 |
| Egg freezing | 58.92 | 77 |
| Ovarian tissue freezing | 28.57 | 49 |
| Oocyte in vitro maturation (IVM) | 28.57 | 23 |
| Artificial ovary | 1.78 | 2 |
| Available fertility preservation options during anticancer treatment | ||
| GnRH analogs | 55.35 | 61 |
| Fractionation of chemo- and radiotherapy | 62.5 | 62 |
| Neoadjuvant cytoprotective pharmacotherapy | 1.78 | 5 |
| Available fertility restoration options after anticancer treatment | ||
| Frozen embryo transfer | 53.57 | 64 |
| IVF/ICSI of frozen oocytes | 55.35 | 75 |
| Autotransplantation of frozen ovarian tissue | 19.64 | 43 |
| Stem cells reproductive technology | 3.57 | 0 |